Aurinia Reports First Quarter 2022 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 1c
May 10, 2022 6:15 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.58 million.
The company maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for... More



